Brief: Arcus Biosciences Announces Clinical Trial Collaboration Agreement To Evaluate Casdatifan In Combination With Volrustomig In Renal Cell Carcinoma
02/10/2024 22:10
Oct 2 (Reuters) - Arcus Biosciences Inc RCUS.N :
* ARCUS BIOSCIENCES ANNOUNCES CLINICAL TRIAL COLLABORATION
AGREEMENT TO EVALUATE CASDATIFAN IN COMBINATION WITH VOLRUSTOMIG
IN RENAL CELL CARCINOMA
* ARCUS BIOSCIENCES INC - ASTRAZENECA TO SPONSOR STUDY ON
CASDATIFAN AND VOLRUSTOMIG COMBINATION
Source text for Eikon: ID:nBw37bZ1La
Further company coverage: RCUS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering